36 / 86
Patient Characteristics
Category
Subgroup
Eribulin (n=228)
n (%)
Dacarbazine (n=224)
n (%)
Histology
ADI
LMS
Other
75 (32.9)
152 (66.7)
1 (0.4)
78 (34.8)
145 (64.7)
1 (0.4)
ADI histological subtype Dedifferentiated
Myxoid/round cell
Pleomorphic
32 (14.0)
30 (13.2)
13 (5.7)
37 (16.5)
26 (11.6)
15 (6.7)
LMS primary site
Uterine
Nonuterine
67 (29.4)
85 (37.3)
62 (27.7)
83 (37.1)
Tumor grade
High
Intermediate
Not done
150 (65.8)
77 (33.8)
1 (0.4)
152 (67.9)
69 (30.8)
3 (1.3)
Number of prior
regimens for advanced
disease
0
1
2
>2
1 (0.4)
15 (6.6)
116 (50.9)
96 (42.1)
1 (0.4)
14 (6.3)
98 (43.8)
111 (49.6)
1. Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502
2. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37
There were no significant differences in baseline characteristics between the 2 treatment
arms